Roche details job cuts, shifts Tamiflu

Share this article:
Roche detailed its “operational excellence” cost-cutting program in a statement, confirming a total workforce reduction of 4,800 jobs, plus another 1,500 positions being either transferred or outsourced to third parties. The program was first announced in September, and will be implemented in 2011 and 2012.
In total, 6,300 jobs will be affected, with 2,650 coming from pharmaceutical sales and marketing, and 3,550 happening in the US, according to the release. Robin Synder, a spokesperson for Roche-owned Genentech, said that no sales and marketing jobs are being outsourced, and that Tamiflu is “the only product going to a CSO,” or contract sales organization.
“This is a comprehensive, focused initiative to reinforce Roche's long-term innovation capability in the face of increased price pressures and a more challenging market environment,” said CEO Severin Schwan, in the announcement. The “main reasons” for sales and marketing reductions, according to the announcement, are taspoglutide, a type two diabetes drug and potential blockbuster, which hit a snag in clinical trials over the summer, and “structural adjustments in the primary care sales organizations, mainly in the US and Europe.”
As part of the restructuring, Roche will focus on late-stage cancer products including T-DM1, pertuzumab and MetMab, according to the announcement. Roche's top selling cancer drugs, Avastin, Rituxan and Herceptin, had US sales of $2.6 billion, $2.3 billion and $1.2 billion, respectively, during the first nine months of 2010, according to company data. Biogen Idec, a partner on Rituxan, recently eliminated 123 sales reps supporting the drug, and handed full commercial duties over to Roche, according to Naomi Aoki, a Biogen Idec spokesperson.
Lucentis picked up a new indication over the summer, and had US sales of $1.1 billion for the first nine months of 2010, a 29% increase compared with the same period in 2009, according to company data.
Share this article:

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.